We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

142 hedge funds and large institutions have $2.38B invested in Soleno Therapeutics in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 14

104% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 28

85% more call options, than puts

Call options by funds: $44.5M | Put options by funds: $24M

33% more capital invested

Capital invested by funds: $1.79B → $2.38B (+$589M)

25% more funds holding

Funds holding: 114 → 142 (+28)

0.75% more ownership

Funds ownership: 120.48% → 121.22% (+0.75%)

10% less funds holding in top 10

Funds holding in top 10: 10 → 9 (-1)

Holders
142
Holders Change
+28
Holders Change %
+24.56%
% of All Funds
2.04%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.13%
New
42
Increased
57
Reduced
28
Closed
14
Calls
$44.5M
Puts
$24M
Net Calls
+$20.5M
Net Calls Change
+$34M

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$46.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.8M
3
Janus Henderson Group
Janus Henderson Group
+$34.6M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$31.9M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$23.7M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$49.1M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$29.8M
3
VPC
Vestal Point Capital
New York
-$23M
4
ABG
Ally Bridge Group
New York
-$11.7M
5
IC
Ikarian Capital
Texas
-$10.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$18.3M +$7.76M +162,112 +81%
Invesco
27
Invesco
Georgia
$16.9M +$15.5M +323,137 +2,929%
EA
28
Emerald Advisers
Pennsylvania
$15.8M +$958K +20,006 +7%
AGP
29
Artia Global Partners
Florida
$13.9M +$8.62M +180,000 +191%
Millennium Management
30
Millennium Management
New York
$12.9M -$9.75M -203,631 -44%
Marshall Wace
31
Marshall Wace
United Kingdom
$12.5M +$11.9M +247,839 New
EMFAT
32
Emerald Mutual Fund Advisers Trust
Pennsylvania
$11.8M -$387K -8,091 -3%
IC
33
Ikarian Capital
Texas
$11.2M -$10.7M -224,014 -50%
ACM
34
Altium Capital Management
New York
$10.7M – – –
Charles Schwab
35
Charles Schwab
California
$9.72M +$6.23M +130,080 +208%
Northern Trust
36
Northern Trust
Illinois
$9.72M +$6.52M +136,185 +241%
GTC
37
Ghost Tree Capital
New York
$7.57M -$7.18M -150,000 -50%
Allspring Global Investments
38
Allspring Global Investments
North Carolina
$7.14M +$375K +7,840 +6%
SC
39
Stempoint Capital
New York
$6.22M +$5.9M +123,177 New
Deutsche Bank
40
Deutsche Bank
Germany
$4.16M +$3.5M +73,015 +771%
Morgan Stanley
41
Morgan Stanley
New York
$3.74M -$909K -18,996 -20%
NFGH
42
Nan Fung Group Holdings
Hong Kong
$3.23M +$3.06M +63,950 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$3.22M -$1.2M -25,044 -28%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$3.19M +$354K +7,400 +13%
Nuveen
45
Nuveen
North Carolina
$3M – – –
CC
46
Checkpoint Capital
California
$2.93M +$1.83M +38,288 +194%
Rafferty Asset Management
47
Rafferty Asset Management
New York
$2.86M +$129K +2,696 +5%
CM
48
Caption Management
Oklahoma
$2.79M -$1.37M -28,526 -34%
SSA
49
Schonfeld Strategic Advisors
New York
$2.74M +$12.2K +254 +0.5%
TC
50
TwinBeech Capital
New York
$2.69M +$2.55M +53,243 New
1
2
3 4 5

SLNO Hedge Fund Activity: Q3 2024 in Review

142 of the 6,971 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2024, worth a combined $2.38B — up 33% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new SLNO positions and 14 closed out — a net gain of 28 holders — while 57 added to existing stakes and 28 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $46.7M. The largest seller was Vivo Capital, cutting an estimated $49.1M.

  • 142 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2024, up from 114 in Q2 2024.
  • Funds reported $2.38B of Soleno Therapeutics stock for Q3 2024, up 33% quarter-over-quarter.
  • 42 funds opened new Soleno Therapeutics positions in Q3 2024 and 14 closed out, a net change of +28 holders.
  • The largest Soleno Therapeutics buyer in Q3 2024 was Alyeska Investment Group, an estimated $46.7M added.
  • The largest Soleno Therapeutics seller in Q3 2024 was Vivo Capital, an estimated $49.1M sold.

Based on aggregated 13F filings for Q3 2024.